ClinicalTrials.gg
CompletedNCT04401800Updated Mar 10, 2025Results posted

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

A Phase 2 interventional study of Lenvatinib and Tislelizumab in Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, sponsored by BeiGene. Completed at 9 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tislelizumab in Carcinoma, Hepatocellular — 23 open to participants now, 25 under way, 2 of them phase 3. tislelizumab · Carcinoma, Hepatocellular.

Enrollment
15th of 43
64 · median 40
Started
2020
with 5 others
Phase 2
31 of 43
16 open now
Registered
3rd of 43
by date
Lead sponsor
5 of 43
BeiGene

Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, this one is the 15th largest by enrollment, is one of 6 that started in 2020, is one of 31 in phase 2, and was the 3rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 43 studies testing tislelizumab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tislelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) by central site imaging facility per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Unresectable Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Able to provide written and can understand and agree to comply with the requirements of the study and the schedule of assessments
  2. Unresectable locally advanced or HCC, which must be confirmed by histologically or cytologically. Fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma histology confirmed by histologically or cytologically is excluded.
  3. Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease that is not amenable to or has progressed after loco-regional therapy and is not amenable to a curative treatment approach
  4. Did not receive any systemic treatment before and is unwilling to accept standard of care treatment or not suitable for standard of care treatment as judged by investigators
  5. At least 1 as defined by v1.1
  6. European Cancer Oncology Group () Performance Status ≤ 1
  7. A classification for liver function assessed within 7 days of first dose of study drugs

Key Exclusion Criteria:

  1. Active diseases or history of autoimmune diseases that may relapse
  2. Any active ≤ 2 years before the first dose of study drugs except for specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)
  3. Uncontrolled diabetes or > Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management, or ≥ Grade 3 hypoalbuminemia ≤ 14 days before the first dose of study drugs
  4. Any known brain or
  5. Concurrent participation in another therapeutic clinical study

NOT: Other protocol defined Inclusion/Exclusion criteria may apply NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Lenvatinib With Tislelizumab

    Participants received lenvatinib based on baseline weight (12 milligrams \[mg\] or 8 mg once daily for participants with a baseline weight of \>= 60 kilograms \[kg\] or \< 60 kg, respectively) along with tislelizumab 200 mg on Day 1 of each 21-day cycle (once every 3 weeks) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

    Drug: Lenvatinib · Drug: Tislelizumab

Interventions

  • Capsules administered orally once daily

  • 200 mg intravenous (IV) infusion administered on Day 1 of each cycle

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.1

    ORR was defined as the percentage of participants achieving the best overall response (BOR) of complete response (CR) or partial response (PR). The 95% confidence interval (CI) was estimated using the Clopper-Pearson method. Per Response evaluation criteria in solid tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation and Modification

    A TEAE was defined as adverse event (AE) that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurs first determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. SAE: any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator.

    Time frame: From the date of the first dose of study drug up to 30 days after last dose of study drug (maximum time on treatment was 12 months)

  2. Objective Response Rate (ORR) as Assessed by the Investigator Based on RECIST v1.1

    ORR was defined as the percentage of participants achieving the BOR of CR or PR. The 95% CI was estimated using the Clopper-Pearson method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; i.e., up to 27 months

  3. Objective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    ORR was defined as the percentage of participants achieving the BOR of CR or PR. The 95% CI was estimated using the Clopper-Pearson method. Per modified RECIST (mRECIST), CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

  4. Objective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST)

    ORR was defined as the percentage of participants achieving the BOR of immune complete response (iCR) or partial response (iPR). The 95% CI was estimated using the Clopper-Pearson method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

  5. Duration of Response (DOR) As Assessed by The Investigator Based on RECIST v1.1

    DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurred earlier). DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)

  6. Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1

    DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurred earlier). DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)

  7. Duration of Response (DOR) As Assessed by The Investigator Based on mRECIST

    DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. PD: an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)

  8. Duration of Response (DOR) As Assessed by the Central Site Imaging Facility Based on mRECIST

    DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. PD: an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)

  9. Duration of Response (DOR) As Assessed by The Investigator Based on iRECIST

    DOR was defined as the time interval between the date of the earliest qualifying response (iCR or iPR) and the date of confirmed progressive disease (iCPD) or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)

  10. Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on iRECIST

    DOR was defined as the time interval between the date of the earliest qualifying response (iCR or iPR) and the date of confirmed progressive disease (iCPD) or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: From the date of earliest response to the date of first documentation of disease progression or death, whichever occurs first (up to 35 months)

  11. Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on RECIST v1.1

    DCR was defined as the percentage of participants with BOR of CR, PR or SD. Participants without post-baseline tumor assessment were considered as failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

  12. Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on mRECIST

    DCR was defined as the percentage of participants with BOR of CR, PR or SD. Participants without post-baseline tumor assessment were considered as failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. Stable disease (SD): any cases that do not qualify for either partial response or progressive disease.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

  13. Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on iRECIST

    DCR was defined as the percentage of participants with BOR of iCR, iPR or immune stable disease (iSD). Participants without post-baseline tumor assessment were considered a failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. iSD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months

  14. Progression Free Survival (PFS) As Assessed by The Investigator Based on RECIST v1.1

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

  15. Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

  16. Progression Free Survival (PFS) As Assessed by The Investigator Based on mRECIST

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per mRECIST, PD was defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

  17. Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on mRECIST

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per mRECIST, PD was defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

  18. Progression Free Survival (PFS) As Assessed by The Investigator Based on iRECIST

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (iCPD) or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per iRECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

  19. Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on iRECIST

    PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (iCPD) or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per iRECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

    Time frame: From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)

07

Results

Posted Mar 10, 2025

Participant flow

The study was conducted at 9 study sites in China.

Participant flow — Overall Study
MilestoneLenvatinib With Tislelizumab
Started64
Completed38
Not completed26
Withdrew: Death17
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by subject4

Outcome measures

PrimaryOverall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.1

ORR was defined as the percentage of participants achieving the best overall response (BOR) of complete response (CR) or partial response (PR). The 95% confidence interval (CI) was estimated using the Clopper-Pearson method. Per Response evaluation criteria in solid tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.1
percentage of participantsLenvatinib With Tislelizumab
Overall Response Rate (ORR) as Assessed by Central Imaging Facility Based on RECIST v1.138.7 (26.6 to 51.9)
Statistical analysis
  • Lenvatinib With Tislelizumab · Binomial exact test · p = 0.0002
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation and Modification

A TEAE was defined as adverse event (AE) that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurs first determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. SAE: any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator.

Time frame:
From the date of the first dose of study drug up to 30 days after last dose of study drug (maximum time on treatment was 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Treatment Discontinuation and Modification
ParticipantsLenvatinib With Tislelizumab
TEAE64
TESAE11
TEAE leading to treatment discontinuation4
TEAE leading to dose modification37
SecondaryObjective Response Rate (ORR) as Assessed by the Investigator Based on RECIST v1.1

ORR was defined as the percentage of participants achieving the BOR of CR or PR. The 95% CI was estimated using the Clopper-Pearson method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; i.e., up to 27 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Assessed by the Investigator Based on RECIST v1.1
percentage of participantsLenvatinib With Tislelizumab
Objective Response Rate (ORR) as Assessed by the Investigator Based on RECIST v1.141.9 (29.5 to 55.2)
Statistical analysis
  • Lenvatinib With Tislelizumab · Binomial exact test · p = < 0.0001
SecondaryObjective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

ORR was defined as the percentage of participants achieving the BOR of CR or PR. The 95% CI was estimated using the Clopper-Pearson method. Per modified RECIST (mRECIST), CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
percentage of participantsLenvatinib With Tislelizumab
By investigator46.8 (34.0 to 59.9)
By Central Site Imaging Facility46.8 (34.0 to 59.9)
Statistical analysis
  • Lenvatinib With Tislelizumab · Binomial exact test · p = < 0.0001
  • Lenvatinib With Tislelizumab · Binomial exact test · p = < 0.0001
SecondaryObjective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST)

ORR was defined as the percentage of participants achieving the BOR of immune complete response (iCR) or partial response (iPR). The 95% CI was estimated using the Clopper-Pearson method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Assessed by the Investigator and Central Site Imaging Facility Based on Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST)
percentage of participantsLenvatinib With Tislelizumab
By investigator43.5 (31.0 to 56.7)
By Central Site Imaging Facility38.7 (26.6 to 51.9)
Statistical analysis
  • Lenvatinib With Tislelizumab · Binomial exact test · p = < 0.0001
  • Lenvatinib With Tislelizumab · Binomial exact test · p = 0.0002
SecondaryDuration of Response (DOR) As Assessed by The Investigator Based on RECIST v1.1

DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurred earlier). DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by The Investigator Based on RECIST v1.1
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by The Investigator Based on RECIST v1.1NA (NA to NA)
SecondaryDuration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1

DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurred earlier). DOR was estimated using the Kaplan-Meier method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1NA (NA to NA)
SecondaryDuration of Response (DOR) As Assessed by The Investigator Based on mRECIST

DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. PD: an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by The Investigator Based on mRECIST
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by The Investigator Based on mRECIST9.7 (5.6 to NA)
SecondaryDuration of Response (DOR) As Assessed by the Central Site Imaging Facility Based on mRECIST

DOR was defined as the time interval between the date of the earliest qualifying response (CR or PR) and the date of PD or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. PD: an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by the Central Site Imaging Facility Based on mRECIST
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by the Central Site Imaging Facility Based on mRECISTNA (NA to NA)
SecondaryDuration of Response (DOR) As Assessed by The Investigator Based on iRECIST

DOR was defined as the time interval between the date of the earliest qualifying response (iCR or iPR) and the date of confirmed progressive disease (iCPD) or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurred first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by The Investigator Based on iRECIST
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by The Investigator Based on iRECISTNA (9.7 to NA)
SecondaryDuration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on iRECIST

DOR was defined as the time interval between the date of the earliest qualifying response (iCR or iPR) and the date of confirmed progressive disease (iCPD) or death (whichever occurs earlier). DOR was estimated using the Kaplan-Meier method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
From the date of earliest response to the date of first documentation of disease progression or death, whichever occurs first (up to 35 months)
Reported as:
Median · months
Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on iRECIST
monthsLenvatinib With Tislelizumab
Duration of Response (DOR) As Assessed by The Central Site Imaging Facility Based on iRECISTNA (NA to NA)
SecondaryDisease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on RECIST v1.1

DCR was defined as the percentage of participants with BOR of CR, PR or SD. Participants without post-baseline tumor assessment were considered as failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on RECIST v1.1
percentage of participantsLenvatinib With Tislelizumab
By investigator85.5 (74.2 to 93.1)
By Central Site Imaging Facility90.3 (80.1 to 96.4)
SecondaryDisease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on mRECIST

DCR was defined as the percentage of participants with BOR of CR, PR or SD. Participants without post-baseline tumor assessment were considered as failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per mRECIST, CR was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. PR: at least a 30% decrease in the sum of diameters of viable (contrast enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. Stable disease (SD): any cases that do not qualify for either partial response or progressive disease.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on mRECIST
percentage of participantsLenvatinib With Tislelizumab
By investigator85.5 (74.2 to 93.1)
By Central Site Imaging Facility90.3 (80.1 to 96.4)
SecondaryDisease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on iRECIST

DCR was defined as the percentage of participants with BOR of iCR, iPR or immune stable disease (iSD). Participants without post-baseline tumor assessment were considered a failure in DCR. The 95% CI was estimated using the Clopper-Pearson method. Per iRECIST, iCR was defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 mm in the short axis. iPR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. iSD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
Response was assessed every 6 weeks for the first year and approximately every 9 weeks thereafter through December 2022; up to 27 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) As Assessed by The Investigator and Central Site Imaging Facility Based on iRECIST
percentage of participantsLenvatinib With Tislelizumab
By investigator88.7 (78.1 to 95.3)
By Central Site Imaging Facility90.3 (80.1 to 96.4)
SecondaryProgression Free Survival (PFS) As Assessed by The Investigator Based on RECIST v1.1

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Investigator Based on RECIST v1.1
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Investigator Based on RECIST v1.19.6 (5.3 to NA)
SecondaryProgression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on RECIST v1.1
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on RECIST v1.18.2 (6.8 to NA)
SecondaryProgression Free Survival (PFS) As Assessed by The Investigator Based on mRECIST

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per mRECIST, PD was defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Investigator Based on mRECIST
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Investigator Based on mRECIST6.9 (4.2 to 9.6)
SecondaryProgression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on mRECIST

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of PD or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per mRECIST, PD was defined as an increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since the treatment started.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on mRECIST
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on mRECIST8.3 (6.7 to NA)
SecondaryProgression Free Survival (PFS) As Assessed by The Investigator Based on iRECIST

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (iCPD) or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per iRECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Investigator Based on iRECIST
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Investigator Based on iRECIST11.1 (6.8 to NA)
SecondaryProgression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on iRECIST

PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (iCPD) or death, whichever occurs first. PFS was estimated using the Kaplan-Meier method. Per iRECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. iRECIST is a modification to RECIST that considers unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression.

Time frame:
From date of first dose of study drug until the date of first documented progression or date of death from any cause, whichever came first (up to 35 months)
Reported as:
Median · months
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on iRECIST
monthsLenvatinib With Tislelizumab
Progression Free Survival (PFS) As Assessed by The Central Site Imaging Facility Based on iRECIST8.2 (6.8 to NA)

Adverse events

Collected over All-cause mortality data were collected through the end of the study, up to 35 months. Adverse events were collected from first dose up to 30 days after last dose; maximum time on treatment was 12 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Lenvatinib17/64 (26.6%)11/64 (17.2%)63/64 (98.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTislelizumab + Lenvatinib
Upper gastrointestinal haemorrhageGastrointestinal disorders2/64
Hepatic function abnormalHepatobiliary disorders2/64
Retinal detachmentEye disorders1/64
Duodenal ulcer perforationGastrointestinal disorders1/64
Gastrointestinal haemorrhageGastrointestinal disorders1/64
Immune-mediated enterocolitisGastrointestinal disorders1/64
PancreatitisGastrointestinal disorders1/64
Pancreatitis acuteGastrointestinal disorders1/64
Small intestinal haemorrhageGastrointestinal disorders1/64
DeathGeneral disorders1/64
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTislelizumab + Lenvatinib
ProteinuriaRenal and urinary disorders29/64
HypertensionVascular disorders23/64
Aspartate aminotransferase increasedInvestigations22/64
HypothyroidismEndocrine disorders20/64
Weight decreasedInvestigations20/64
Platelet count decreasedInvestigations17/64
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders13/64
Blood bilirubin increasedInvestigations12/64
Lipase increasedInvestigations12/64
DiarrhoeaGastrointestinal disorders11/64

Baseline characteristics

Analysis was performed on safety analysis set which included all participants who received at least 1 dose of any study drug (any component for the combination therapy).

Age, Continuous
Age, Continuous(years)Lenvatinib With Tislelizumab
Mean51.1 ± 11.24
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib With Tislelizumab
Female11
Male53
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib With Tislelizumab
Hispanic or Latino0
Not Hispanic or Latino64
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib With Tislelizumab
American Indian or Alaska Native0
Asian64
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

9 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shaanxi 710061, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200092, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2022, 26 months.

Results were first posted in Mar 2025, 2 years 3 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 26 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
May 26, 2020
StartActual
Sep 4, 2020
Primary completionActual
Dec 1, 2022
CompletionActual
Feb 18, 2024
Results first posted
Mar 10, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04401800
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
May 26, 2020
Start date
Sep 4, 2020
Primary completion
Dec 1, 2022
Completion
Feb 18, 2024
Results posted
Mar 10, 2025
Last update
Mar 10, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion